These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 29414722)
1. Crystal-induced oligoarthritis triggered by pembrolizumab, an immune checkpoint inhibitor. Corominas H; Badlissi F; Shmerling RH Joint Bone Spine; 2018 Oct; 85(5):647-648. PubMed ID: 29414722 [No Abstract] [Full Text] [Related]
2. A case of arthritis under pembrolizumab. Salmon JH; Lambrecht I; Brochot P; Grange F Joint Bone Spine; 2017 Mar; 84(2):243-244. PubMed ID: 27118015 [No Abstract] [Full Text] [Related]
3. Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma. Garel B; Kramkimel N; Trouvin AP; Frantz C; Dupin N Joint Bone Spine; 2017 Mar; 84(2):233-234. PubMed ID: 27133763 [No Abstract] [Full Text] [Related]
4. Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma. Schmidgen MI; Butsch F; Schadmand-Fischer S; Steinbrink K; Grabbe S; Weidenthaler-Barth B; Loquai C J Dtsch Dermatol Ges; 2017 Jul; 15(7):742-745. PubMed ID: 28622432 [No Abstract] [Full Text] [Related]
5. Pembrolizumab versus Ipilimumab in Advanced Melanoma. Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A; N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173 [TBL] [Abstract][Full Text] [Related]
6. [Treating metastatic melanoma: Risk management]. Lebbe C; Robert C Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593 [No Abstract] [Full Text] [Related]
7. Safety of pembrolizumab for the treatment of melanoma. Martin-Liberal J; Kordbacheh T; Larkin J Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979 [TBL] [Abstract][Full Text] [Related]
8. A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment. Humayun MA; Poole R Hormones (Athens); 2016 Apr; 15(2):303-306. PubMed ID: 27376434 [No Abstract] [Full Text] [Related]
9. Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma. Amber KT; Valdebran M; Lu Y; De Feraudy S; Linden KG J Dtsch Dermatol Ges; 2018 Feb; 16(2):196-198. PubMed ID: 29389067 [No Abstract] [Full Text] [Related]
14. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Longoria TC; Tewari KS Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741 [TBL] [Abstract][Full Text] [Related]
17. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415 [TBL] [Abstract][Full Text] [Related]
18. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma. Woodbeck R; Metelitsa AI; Naert KA Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748 [TBL] [Abstract][Full Text] [Related]
19. Spotlight on pembrolizumab in the treatment of advanced melanoma. Rajakulendran T; Adam DN Drug Des Devel Ther; 2015; 9():2883-6. PubMed ID: 26082618 [TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab for treatment of refractory melanoma. Bagcchi S Lancet Oncol; 2014 Sep; 15(10):e419. PubMed ID: 25328942 [No Abstract] [Full Text] [Related] [Next] [New Search]